LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Coworking blueprint for contractors trades home for critical back-office business support
Trades CoWork provides a professional office environment, storage space, and back-office support to contractors and trades workers who have long been “dismissed,” said William Hayes, an entrepreneur who “sold everything” to fuel the venture. “There is nothing out there for the small contractors that gives them an affordable option to move out of their house,…
Why these Big Jay collectibles are a nod to bobblehead hall of fame’s love of KC-area sports
A cross-country childhood trip to the Negro Leagues Baseball Museum inspired a young baseball fan and rookie sports collector to keep Kansas City on his map — later incorporating an array of local major league and collegiate teams into his entrepreneurial venture: a national hall of fame for bobbleheads. The most recent additions to his…
Federal ban on noncompetes would ‘unleash’ entrepreneurs, open door to more startups, advocate says
A proposed rule change that would stop employers from imposing and enforcing contract clauses to limit their workers’ ability to change jobs within their fields is being hailed as a “vital step on the path to expanding economic growth in the United States,” according to one Kansas City-based advocate for entrepreneurs. Earlier this month, the…
Ice Cream Bae returns to the Country Club Plaza with its own storefront, more flavors
Adison and Jackie Sichampanakhone have a soft spot for the Country Club Plaza, they shared. It’s where the journey with their soft-serve ice cream shop began. “We’re excited to be back. We had so many great customers down here before, so we’re happy to be able to serve them again,” said Adison, who co-founded Ice…